Considerations for the development of therapeutic monoclonal antibodies
- 31 August 2008
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Immunology
- Vol. 20 (4), 493-499
- https://doi.org/10.1016/j.coi.2008.05.013
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Structural and Functional Characterization of Disulfide Isoforms of the Human IgG2 SubclassPublished by Elsevier BV ,2008
- Human IgG2 Antibodies Display Disulfide-mediated Structural IsoformsPublished by Elsevier BV ,2008
- The growth and potential of human antiviral monoclonal antibody therapeuticsNature Biotechnology, 2007
- Isotype selection in antibody engineeringNature Biotechnology, 2007
- What's fueling the biotech engine?Nature Biotechnology, 2007
- Development trends for monoclonal antibody cancer therapeuticsNature Reviews Drug Discovery, 2007
- Anti-infective monoclonal antibodies: perils and promise of developmentNature Reviews Drug Discovery, 2006
- Monoclonal antibody successes in the clinicNature Biotechnology, 2005
- Human IgG2 Can Form Covalent DimersPublished by The American Association of Immunologists ,2003
- Clinical trials of antibody therapyImmunology Today, 2000